{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=19", "query": { "intervention": "Placebo- matched", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 7051, "total_pages": 706, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T20:08:35.843Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07284979", "title": "Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Ribupatide", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kailera", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1270, "start_date": "2025-12-30", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-09T20:08:35.843Z", "location_count": 28, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Northridge", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07284979" }, { "nct_id": "NCT01974440", "title": "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "PCI-32765 (Ibrutinib)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 403, "start_date": "2014-01-31", "completion_date": "2023-06-21", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-11-09T20:08:35.843Z", "location_count": 32, "location_summary": "Gilbert, Arizona • Campbell, California • Duarte, California + 29 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01974440" }, { "nct_id": "NCT07378579", "title": "An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "ESK-001", "type": "DRUG" }, { "name": "Moxifloxacin (400 mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alumis Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 52, "start_date": "2024-06-21", "completion_date": "2024-08-31", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-11-09T20:08:35.843Z", "location_count": 1, "location_summary": "Daytona Beach, Florida", "locations": [ { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07378579" }, { "nct_id": "NCT02469090", "title": "Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson Disease, Off Episodes" ], "interventions": [ { "name": "APL-130277", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 141, "start_date": "2015-06-18", "completion_date": "2017-12-11", "has_results": true, "last_update_posted_date": "2020-07-30", "last_synced_at": "2026-11-09T20:08:35.843Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02469090" }, { "nct_id": "NCT07247162", "title": "Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension", "Hypercortisolemia", "Cushing Syndrome" ], "interventions": [ { "name": "Osilodrostat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RECORDATI GROUP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2026-08-26", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-09T20:08:35.843Z", "location_count": 3, "location_summary": "Jacksonville, Florida • Canton, Ohio • Weslaco, Texas", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Canton", "state": "Ohio" }, { "city": "Weslaco", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07247162" }, { "nct_id": "NCT06819891", "title": "A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderately to Severely Active Crohns Disease" ], "interventions": [ { "name": "Afimkibart", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 425, "start_date": "2025-05-12", "completion_date": "2033-04-30", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-09T20:08:35.843Z", "location_count": 64, "location_summary": "Dothan, Alabama • Glendale, Arizona • Lancaster, California + 57 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Lancaster", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Pomona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06819891" }, { "nct_id": "NCT03630627", "title": "A Phase I Study of SB26 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "SB26", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Samsung Bioepis Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 58, "start_date": "2018-08-22", "completion_date": "2020-04-16", "has_results": false, "last_update_posted_date": "2020-04-24", "last_synced_at": "2026-11-09T20:08:35.843Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03630627" }, { "nct_id": "NCT03325881", "title": "Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Attention Deficit Hyperactivity Disorder (ADHD)" ], "interventions": [ { "name": "SHP465", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "6 Years to 12 Years" }, "enrollment_count": 89, "start_date": "2017-12-09", "completion_date": "2018-06-07", "has_results": true, "last_update_posted_date": "2021-06-02", "last_synced_at": "2026-11-09T20:08:35.843Z", "location_count": 41, "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Rolling Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03325881" }, { "nct_id": "NCT07473544", "title": "Essential Oil Inhalation and Acute Stress Response in Healthy Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Psychological Stress" ], "interventions": [ { "name": "Essential Oil Inhalation", "type": "OTHER" }, { "name": "Placebo Aroma Stick", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "dōTERRA International", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 200, "start_date": "2026-03-10", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-11-09T20:08:35.843Z", "location_count": 1, "location_summary": "Pleasant Grove, Utah", "locations": [ { "city": "Pleasant Grove", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07473544" }, { "nct_id": "NCT00507507", "title": "A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "Tenofovir DF", "type": "DRUG" }, { "name": "FTC", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 126, "start_date": "2007-09", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2015-07-17", "last_synced_at": "2026-11-09T20:08:35.843Z", "location_count": 10, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00507507" } ] }